The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
News|Articles|May 4, 2026
5 Nephrology Headlines You Missed in April 2026
Author(s)Alex Hillenbrand
Fact checked by: Victoria Johnson
Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data.
Advertisement
Advertisement
April 2026 marked a pivotal month in
Related to this article
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
The FDA has pushed its decision on mitapivat for sickle cell disease to February 1, 2027, while it reviews updated safety data to decide whether a REMS is needed.
Stephen Seliger, MD, and Michel Chonchol, MD, join Kidney Compass to discuss a pilot trial of empagliflozin in rapidly progressing ADPKD.
Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.
Advertisement
Advertisement